Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Labcorp Holdings Inc.

LH

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

Last trade $369.56
Day change -$2.905 (-0.78%)
Day range $368.70 – $377.06
Volume 322,001
Market cap $30.24B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$30.24B
Price / earnings
30.12×
Price / book
3.42×
Price / sales
2.07×
EV / sales
2.46×
EV / EBITDA
15.26×

Profitability

Earnings per share
$12.36
Return on assets
5.31%
Return on equity
11.35%
Dividend yield
0.78%

Liquidity and leverage

Debt / equity
0.67×
Current ratio
1.41×
Quick ratio
1.22×
Cash ratio
0.09×

Cash flow

Price / cash flow
16.66×
Price / free cash flow
23.5×
Free cash flow
$1.29B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LH, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$3.81B$3.73B$3.54B$3.52B$3.56B$3.53B$3.35B$3.33B
Cost of revenue$2.7B$2.62B$2.52B$2.52B$2.54B$2.48B$2.4B$2.43B
Gross profit$1.11B$1.11B$1.01B$993.2M$1.03B$1.05B$948M$896.3M
Selling, general and administrative$611.4M$577.2M$551M$538.6M$553.1M$579.3M$546M$595.2M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$706M$660.4M$633M$725.6M$628.5M$651.7M$622M$679.8M
Operating income$402.1M$451.6M$380.8M$267.6M$396.6M$394.5M$326M$216.5M
Interest expense-$59.1M-$61.1M-$55.1M-$55M-$56M-$57.1M-$56M-$63.4M
Income before taxes$328M$386.4M$319.7M$190.6M$337M$304.7M$275.2M$183.8M
Income taxes$64.9M$87.3M$41.7M$25.7M$75.5M$66.4M$62.2M$40.2M
Net income$263.1M$299.1M$278M$164.9M$261.5M$238.3M$213M$143.6M
Net income attributable to common shareholders$262.8M$298.7M$277.8M$164.7M$261.1M$237.9M$212.8M$143.4M
EBITDA$601M$635.7M$560.5M$555M$573.5M$568.9M$499.2M$401.3M
Basic earnings per share$3.24$3.66$3.37$1.99$3.14$2.85$2.54$1.72
Diluted earnings per share$3.22$3.64$3.35$1.98$3.12$2.84$2.52$1.70

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Labcorp: 3 Key Takeaways for Long-Term Investors

Labcorp reported 7% revenue growth to $3.8 billion in Q3 2026 with raised full-year guidance. The company faces a $125 million Medicare reimbursement headwind from proposed PAMA fee schedule changes in 2027, but plans to offset this through volume growth and cost efficiencies. Specialty testing is growing 3x faster than the broader diagnostics market, and tuck-in acquisitions from BioReference, Myriad Genetics' prenatal business, and Millennium Health are expected to be accretive to earnings in year one.

Zacks Investment Research

Is Now the Right Time to Hold Labcorp Stock in Your Portfolio?

Labcorp Holdings (LH) has surged 48.2% year-to-date, driven by expansion in specialty testing markets, AI and automation initiatives, and six consecutive quarters of margin expansion. However, currency headwinds, intense competition, and acquisition-related execution risks could limit future growth. The company maintains a Zacks Rank #3 (Hold) with a 5% earnings yield.

Zacks Investment Research

Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?

Labcorp Holdings (LH), a leading healthcare diagnostics company, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a VGM Score of B. The company has attractive valuation metrics with a forward P/E ratio of 20.01 and has seen six analyst upward earnings revisions in the last 60 days, with the Zacks Consensus Estimate increasing to $18.40 per share.

Zacks Investment Research

Stock Market News for Oct 29, 2026

U.S. stock markets rose on Wednesday as the Federal Reserve kept interest rates unchanged at 3.75-4% and strong third-quarter earnings boosted investor confidence. The Dow Jones, Nasdaq Composite, and S&P 500 all ended in positive territory. Notable earnings beats from Seagate Technology, Amphenol Corp., and Labcorp Holdings drove their stock prices higher by 4.5%, 3.5%, and 8.8% respectively.

Zacks Investment Research

LH Stock Rises on Q3 Earnings and Revenue Beat, '26 View Up

Labcorp Holdings (LH) reported Q3 2026 adjusted EPS of $4.78, up 14.5% year-over-year, and revenues of $3.81 billion, up 6.9%, both beating consensus estimates. The company raised its full-year 2026 revenue guidance to 5.9-6.7% and adjusted EPS guidance to $18.30-$18.70, driven by strong organic growth across both Diagnostics and Biopharma Laboratory Services segments and margin expansion.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.72 per share
Declared
Oct 20, 2026
Ex-dividend
Nov 24, 2026
Pay date
Dec 11, 2026
Ex-dividendAmount / sharePay dateType
Aug 28, 2026$0.72Sep 11, 2026recurring
May 29, 2026$0.72Jun 11, 2026recurring
Feb 27, 2026$0.72Mar 12, 2026recurring
Nov 26, 2025$0.72Dec 11, 2025recurring
Aug 28, 2025$0.72Sep 11, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 3, 20231,164-for-1,000forward split